Literature DB >> 18765134

Update on minimally invasive therapy for chronic prostatitis/chronic pelvic pain syndrome.

Christof Kastner1.   

Abstract

Once primary treatment fails, the diverse causes and symptoms of chronic pelvic pain syndrome require clinicians to consider several secondary approaches. Multimodal therapy addresses unique symptoms and targets illness origin. However, once medical modalities fail, minimally invasive therapies should be considered, including transurethral needle ablation hyperthermia, cooled thermotherapy, electromagnetic chair, prostatic massage, and intraprostatic botulinum toxin A injection. Low evidence levels exist for all approaches, but we anticipate promising results of larger trials for cooled thermotherapy and look forward to the emergence of experimental techniques using botulinum toxin A.

Entities:  

Mesh:

Year:  2008        PMID: 18765134     DOI: 10.1007/s11934-008-0057-5

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  19 in total

Review 1.  A review of clinical and pathological prostatitis syndromes.

Authors:  R O Roberts; M M Lieber; D G Bostwick; S J Jacobsen
Journal:  Urology       Date:  1997-06       Impact factor: 2.649

2.  Evaluation of prostatic massage in treatment of chronic prostatitis.

Authors:  Ahmad Ateya; Ashraf Fayez; Ragab Hani; Wael Zohdy; Mohammad A Gabbar; Rany Shamloul
Journal:  Urology       Date:  2006-03-29       Impact factor: 2.649

3.  The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network.

Authors:  M S Litwin; M McNaughton-Collins; F J Fowler; J C Nickel; E A Calhoun; M A Pontari; R B Alexander; J T Farrar; M P O'Leary
Journal:  J Urol       Date:  1999-08       Impact factor: 7.450

Review 4.  Prostatitis unplugged? Prostatic massage revisited.

Authors:  J C Nickel; R Alexander; R Anderson; J Krieger; T Moon; D Neal; A Schaeffer; D Shoskes
Journal:  Tech Urol       Date:  1999-03

5.  How common is prostatitis? A national survey of physician visits.

Authors:  M M Collins; R S Stafford; M P O'Leary; M J Barry
Journal:  J Urol       Date:  1998-04       Impact factor: 7.450

6.  A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup.

Authors:  E Rowe; C Smith; L Laverick; J Elkabir; R O'N Witherow; A Patel
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

7.  Transurethral needle ablation for the treatment of chronic pelvic pain syndrome (category III prostatitis): a randomized, sham-controlled study.

Authors:  Markku J Leskinen; Ansa Kilponen; Olavi Lukkarinen; Teuvo L J Tammela
Journal:  Urology       Date:  2002-08       Impact factor: 2.649

8.  Clinical experience with transurethral microwave thermotherapy for chronic nonbacterial prostatitis and prostatodynia.

Authors:  N G Choi; S H Soh; T H Yoon; M H Song
Journal:  J Endourol       Date:  1994-02       Impact factor: 2.942

9.  Transurethral microwave thermotherapy for nonbacterial prostatitis: a randomized double-blind sham controlled study using new prostatitis specific assessment questionnaires.

Authors:  J C Nickel; R Sorensen
Journal:  J Urol       Date:  1996-06       Impact factor: 7.450

10.  Cooled thermotherapy for the treatment of benign prostatic hyperplasia: durability of results obtained with the Targis System.

Authors:  Paul D Miller; Christof Kastner; Ernest W Ramsey; Keith Parsons
Journal:  Urology       Date:  2003-06       Impact factor: 2.649

View more
  2 in total

Review 1.  A review of botulinum toxin use for chronic pelvic pain syndrome.

Authors:  Henry P Gottsch; Claire C Yang; Richard E Berger
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

2.  Evaluation of chronic pelvic pain syndrome in men: is it chronic prostatitis?

Authors:  Raymond M Bernal; Michel A Pontari
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.